SCHEMBL10126468

SCHEMBL10126468

CCN(CC)S(=O)(=O)c1ccc(C)c(Nc2nc(SC)nc(Cl)c2C(N)=O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.43
KMT2A Q03164 2/20 0.43
CYP2C9 P11712 1/20 0.43
LMNA P02545 5/20 0.42
MAPT P10636 3/20 0.42
BRD4 O60885 1/20 0.42
BRPF1 P55201 1/20 0.42
HTT P42858 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MDM4 O15151 1/20 0.41
MITF O75030 1/20 0.41
MDM2 Q00987 1/20 0.41
ATM Q13315 1/20 0.41
GPR35 Q9HC97 1/20 0.41
KDM4E B2RXH2 4/20 0.41
MEN1 O00255 1/20 0.41
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
PKM P14618 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10126504 0.84 TNNI3K (0.46) LMNAMAPTBRD4
SCHEMBL10126496 0.82 CA1 (0.39) ALDH1A1KMT2AMAPTMEN1
SCHEMBL10126464 0.81 ALDH1A1 (0.47) ALDH1A1KMT2ACYP2C9LMNAMAPT
SCHEMBL16305343 0.81 HPGD (0.40) ALDH1A1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL10126471 0.80 HTT (0.49) ALDH1A1KMT2ALMNAMAPTHTT
SCHEMBL10126444 0.78 MAPK3 (0.43) ALDH1A1KMT2ALMNAMAPTHTT
SCHEMBL10156456 0.76 SMN1; SMN2 (0.45) ALDH1A1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL16305323 0.76 MAPK14 (0.43) MAPT
SCHEMBL10156657 0.75 TNNI3K (0.47) ALDH1A1KMT2ALMNAMAPTBRD4
SCHEMBL10156677 0.74 CCNB2 (0.45) ALDH1A1KMT2ALMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885KMT2A 103/4885CYP2C9 4151/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885KMT2A 103/4885CYP2C9 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.